Table 5

Validation of the novel criteria of COVID-CS

COVID-CS new criteriaConsensus storm
N%LoS (days)*Mortality (%)*NoYes
All group
No340665.7±6.76.633010
Yes1733415.1±1328.811954
SP=0.73SE=0.84
ACC=0.75
No trials group
No30871.55.3±6.76.43008
Yes12328.515.3±13.728.17845
SP=0.79SE=0.85
ACC=0.80
  • The new COVID-CS criteria were applied to the cohort (left) and to the same patients divided according to the clinical consensus of cytokine storm (right). All group includes all the COVID-19 cohort (513, 64 patients who reached and 449 who did not reach the clinical consensus of COVID-19 cytokine storm). No trials group includes 431 patients of the cohort because it excludes 82 patients with COVID-19 who were recruited in clinical trials testing biologic therapies. The new criteria identified patients with significantly greater LoS and mortality.

  • *P<0.0001.

  • ACC, accuracy; COVID-CS, COVID-19 cytokine storm; LoS, length of stay; SE, sensitivity; SP, specificity.